Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Tax Provisions (2019 - 2024)

C4 Therapeutics' Tax Provisions history spans 4 years, with the latest figure at $131000.0 for Q4 2024.

  • For Q4 2024, Tax Provisions fell 53.21% year-over-year to $131000.0; the TTM value through Dec 2024 reached $131000.0, down 89.79%, while the annual FY2025 figure was $121000.0, 7.63% down from the prior year.
  • Tax Provisions reached $131000.0 in Q4 2024 per CCCC's latest filing, down from $280000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $1.0 million in Q3 2023 to a low of -$168000.0 in Q2 2020.
  • Average Tax Provisions over 3 years is $112571.4, with a median of -$124000.0 recorded in 2020.
  • The largest YoY upside for Tax Provisions was 29.17% in 2020 against a maximum downside of 125.69% in 2020.
  • A 3-year view of Tax Provisions shows it stood at -$124000.0 in 2020, then soared by 325.81% to $280000.0 in 2023, then tumbled by 53.21% to $131000.0 in 2024.
  • Per Business Quant, the three most recent readings for CCCC's Tax Provisions are $131000.0 (Q4 2024), $280000.0 (Q4 2023), and $1.0 million (Q3 2023).